The enhanced radiosensitivity and increased cellular stiffness of IDH1R132H-positive glioma cells are consistent with the clinical observation of a less aggressive tumor and a prolonged survival of diffuse glioma patients harboring the IDH1 mutation. Here, IDH1 is linked to central nervous system cancer.